EOS-984 is under clinical development by ITeos Therapeutics and currently in Phase I for Advanced Malignancy. According to GlobalData, Phase I drugs for Advanced Malignancy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EOS-984 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EOS-984 overview
EOS-984 is under development for the treatment of advanced malignancies. It acts by a new mechanism that modulates T cell activation and proliferation in high adenosine concentration and is additive to A2A antagonist.
ITeos Therapeutics overview
iTeos Therapeutics is a clinical-stage biopharmaceutical company. It discovers and develops immuno-oncology drugs for cancer. The company’s pipeline products are EOS-448, EOS-984, dostarlimab, iberdomide, pembrolizumab, CD96 drug candidates. Its products are used to treat various cancers like advanced malignancies, relapsed refractory multiple myeloma. The drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations. Its service includes to carries out clinical trials for inupadenant, an A2A receptor antagonist, as a treatment for solid tumors in monotherapy. It has operational presence in the US; and Belgium. iTeos Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of EOS-984’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
